NCT02471170Enrolling by invitation
Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to collect blood samples to detect potential markers of pancreatic cancer in the blood and link these findings to medical and health information. Information from this study may help to provide insight into the detection of pancreas cancer in the blood before it can be found by other methods or provide a method of monitoring the status of pancreatic cancer throughout a treatment course. Another purpose of this study is to collect blood to create a biobank.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 11 Jun 2015
- Start date
- 10 Sept 2015
- Primary completion date
- 1 Jan 2035
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Pancreatic cancer
- NCT number
- NCT02471170
What you commit to
- Study type: Observational
- Planned participants: 100
- From 10 Sept 2015 to the primary completion date, 1 Jan 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Subject is under 18 years of age
Other
- The subject or acceptable surrogate does not provide informed consent
- Subject is a prisoner
Who the study is looking for
- The subject must be a patient at the Hospital of the University of Pennsylvania
- The subject must be under evaluation and/or treatment for a pancreatic disease
- The subject must be under evaluation and/or treatment for a non-pancreatic disease. For example, patients undergoing routine colonoscopy within the clinical practice will be asked to consent to provide control samples.
- The subject must be able to provide informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf
- The subject must be 18 years of age or older
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abramson Cancer Center of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.